4.7 Article

Multivitamins in the Prevention of Cardiovascular Disease in Men The Physicians' Health Study II Randomized Controlled Trial

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 308, 期 17, 页码 1751-1760

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2012.14805

关键词

-

资金

  1. NIH (Bethesda, Maryland) [CA 097193, CA 34944, CA 40360, HL 26490, HL 34595]
  2. BASF Corporation (Florham Park, New Jersey)
  3. Tomato Products Wellness Council
  4. National Institutes of Health (NIH)
  5. Cambridge Theranostics Ltd.
  6. Harvard University (Clinical Nutrition Research Center)
  7. DSM Nutritional Products Inc
  8. nonprofit Aurora Foundation
  9. Bristol-Meyers Squibb
  10. AstraZeneca
  11. Novartis
  12. Veterans Administration
  13. BASF Corporation

向作者/读者索取更多资源

Context Although multivitamins are used to prevent vitamin and mineral deficiency, there is a perception that multivitamins may prevent cardiovascular disease (CVD). Observational studies have shown inconsistent associations between regular multivitamin use and CVD, with no long-term clinical trials of multivitamin use. Objective To determine whether long-term multivitamin supplementation decreases the risk of major cardiovascular events among men. Design, Setting, and Participants The Physicians' Health Study II, a randomized, double-blind, placebo-controlled trial of a common daily multivitamin, began in 1997 with continued treatment and follow-up through June 1, 2011. A total of 14 641 male US physicians initially aged 50 years or older (mean, 64.3 [SD, 9.2] years), including 754 men with a history of CVD at randomization, were enrolled. Intervention Daily multivitamin or placebo. Main Outcome Measures Composite end point of major cardiovascular events, including nonfatal myocardial infarction (MI), nonfatal stroke, and CVD mortality. Secondary outcomes included MI and stroke individually. Results During a median follow-up of 11.2 (interquartile range, 10.7-13.3) years, there were 1732 confirmed major cardiovascular events. Compared with placebo, there was no significant effect of a daily multivitamin on major cardiovascular events (11.0 and 10.8 events per 1000 person-years for multivitamin vs placebo, respectively; hazard ratio [HR], 1.01; 95% CI, 0.91-1.10; P=.91). Further, a daily multivitamin had no effect on total MI (3.9 and 4.2 events per 1000 person-years; HR, 0.93; 95% CI, 0.80-1.09; P=.39), total stroke (4.1 and 3.9 events per 1000 person-years; HR, 1.06; 95% CI, 0.91-1.23; P=.48), or CVD mortality (5.0 and 5.1 events per 1000 person-years; HR, 0.95; 95% CI, 0.83-1.09; P=.47). A daily multivitamin was also not significantly associated with total mortality (HR, 0.94; 95% CI, 0.88-1.02; P=.13). The effect of a daily multivitamin on major cardiovascular events did not differ between men with or without a baseline history of CVD (P=.62 for interaction). Conclusion Among this population of US male physicians, taking a daily multivitamin did not reduce major cardiovascular events, MI, stroke, and CVD mortality after more than a decade of treatment and follow-up.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据